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Abstract
Background
Preeclampsia is one of the leading causes of maternal and neonatal morbidity and mortality
in the world, but its appearance is still unpredictable and its pathophysiology has not been
entirely elucidated. Genetic studies have associated single nucleotide polymorphisms in
genes encoding nitric oxide synthase and matrix metalloproteases with preeclampsia, but
the results are largely inconclusive across different populations.
Objectives
To investigate the association of single nucleotide polymorphisms (SNPs) in NOS3
(G894T, T-786C, and a variable number of tandem repetitions VNTR in intron 4),MMP2
(C-1306T), andMMP9 (C-1562T) genes with preeclampsia in patients from Southeastern
Brazil.
Methods
This prospective case-control study enrolled 77 women with preeclampsia and 266 control
pregnant women. Clinical data were collected to assess risk factors and the presence of
severe complications, such as eclampsia and HELLP (hemolysis, elevated liver enzymes,
and low platelets) syndrome.
Results
We found a significant association between the single nucleotide polymorphism NOS3
T-786C and preeclampsia, independently from age, height, weight, or the other SNPs
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studied, and no association was found with the other polymorphisms. Age and history of
preeclampsia were also identified as risk factors. The presence of at least one polymorphic
allele for NOS3 T-786C was also associated with the occurrence of eclampsia or HELLP
syndrome among preeclamptic women.
Conclusions
Our data support that the NOS3 T-786C SNP is associated with preeclampsia and the
severity of its complications.
Introduction
Preeclampsia is a multisystem pregnancy-specific disease, with varying clinical features, that
affects 2–8% of pregnancies worldwide and is a major cause of maternal morbidity and mortal-
ity[1,2], especially in low and middle income countries[3,4], accounting for short and long-
term health consequences for mothers and offspring[2,5]. There is a global concern on its ris-
ing incidence, mostly due to increasing rates of underlying and predisposing disorders such as
chronic hypertension, diabetes and obesity[1,6].
The definition of preeclampsia was recently revised[7] to take into consideration new onset
hypertension developing after 20 weeks gestation as well as the coexistence of one or more of
the following: proteinuria, other maternal organ dysfunction (renal insufficiency, liver involve-
ment; neurological complications or hematological complications) and/or uteroplacental dys-
function reflected by fetal growth restriction. Severe preeclampsia is considered in the presence
of extremely high blood pressure (systolic blood pressure over 160mmHg and diastolic over
110mmHg), symptoms of impeding eclampsia, or diagnosis of HELLP (hemolysis, elevated
liver enzymes, and low platelets) syndrome. According to time of onset of preeclampsia, early-
onset is characterized when the disease presents before 34 weeks of gestation.
Despite extensive research on this topic, the exact causes of this malady remain largely
unknown, with strong hypotheses implicating a disturbance of the placental function early in
pregnancy that is associated with impaired spiral arteries remodeling and exacerbated inflam-
matory response[8]. The role of genetics is still not well defined; however, there is clear evi-
dence of the risk factor played by family history, supported by twin studies, segregation and
linkage analyses, as well as genome-wide association studies[9–12].
Several studies have identified single nucleotide polymorphisms (SNPs) that may be associ-
ated with preeclampsia. The NOS3 gene is located on the long arm of chromosome 7
(7q35-q36 region) and encodes the enzyme endothelial nitric oxide synthase (eNOS)[13],
responsible for the production of nitric oxide (NO). NO is involved in the regulation of blood
pressure, blood flow distribution to the organs, inhibition of platelet adhesion and aggregation,
and inhibition of some leukocyte functions[14]. Some SNPs including T-786C, G894T
(Glu298Asp), and a variable number of tandem repeats (VNTR) in intron 4 have been identi-
fied[15–17] and can influence NO production.
The G894T polymorphism has been associated with a reduction in endothelium-dependent
vasodilation in pregnancy and with the risk for ischemic heart disease[18,19]. However, in pre-
eclampsia, the results have been conflicting: some studies show association of this polymor-
phism with the disease, while others disagree[20–25].
The T-786C SNP causes significant reduction of eNOS activity, may be associated with a
predisposition to hypertension in general, and is also associated with reduced eNOS mRNA in
SNPs Associated with Preeclampsia
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the placenta[17,26]. One study has suggested the need for replication of their finding of this
polymorphism as a risk factor for preeclampsia[24].
Similarly to eNOS, extracellular matrix metalloproteases (MMPs) are another group of
enzymes that can modulate blood flow in the vessels. MMPs induce cleavage of calcitonin
gene-related peptide, and of "big endothelin" (ET-1), producing its most active form, ET-1 [1–
32], favoring vasoconstriction[27,28]. Increased activity of MMPs seems to play a role in pre-
eclampsia, as plasma levels of MMP-2 have been found to be elevated in patients with pre-
eclampsia[29], so SNPs in genes encoding MMPs have been studied as biomarkers of
susceptibility to preeclampsia.
SNPs in theMMP2 gene have been less studied than NOS3, and despite their association
with increased levels of MMP-2, SNPs C-1306T and C-735T have not been identified as bio-
markers of susceptibility in one population and warrant further studies[30].
SNP C-1562T in the gene encoding MMP-9 has been implicated in an increase in gene
expression in individuals carrying the polymorphic allele T[31]. This SNP has been associated
with hypertension in the general population[32–34] and with gestational hypertension, but
susceptibility to preeclampsia has been controversial across different populations[30,35–38].
We aimed at shedding light on the controversial role of these polymorphisms by performing
a case-control study of preeclamptic and normotensive pregnant women. We compared the
distribution of genotypes for NOS3 G894T, T-786C, and VNTR in intron 4, as well asMMP2
C-1306T andMMP9 C-1562T, and tested their association with preeclampsia and its major
complications.
Materials and Methods
Ethics statement
This study was approved by the local Ethics Board of the Hospital da Mulher Prof. Dr. José
Aristodemo Pinotti, Centro de Atenção Integral à Saúde da Mulher–CAISM, a public regional
reference hospital for Obstetrics and Gynecology in Campinas, Brazil (approval number 502/
2010). Written informed consent was obtained from all subjects.
Patient enrollment
Inclusion criteria for cases were pregnancy between 20 and 40 weeks or post-partum, and pre-
eclampsia as defined by new onset of hypertension with systolic blood pressure (BP) above
140mmHg or diastolic BP above 90mmHg, in association with either proteinuria above 300mg
in 24h or a positive urine dipstick test equal to or above 2+ in the absence of urinary infection
[39]. Inclusion criteria for controls were pregnancy between 20 and 40 weeks or post-partum
and absence of any of the diagnostic criteria for preeclampsia until discharge after delivery,
including a negative urine dipstick test or normal 24-hour proteinuria. Exclusion criteria for
both groups were multiple gestation, fetal malformations, arterial hypertension, gestational
hypertension, diabetes mellitus, autoimmune diseases, thyroid disease, and chronic infectious
diseases.
Genotype determination
Peripheral venous blood samples were collected in tubes containing EDTA and stored at 4
degrees Celsius until the time of processing. All samples were numbered upon enrollment and
laboratory personnel were blinded to the diagnostic group allocation until the genotyping
phase was finished. Genomic DNA was obtained using phenol-chloroform modified technique
[40]. NOS3 G894T and T-786C,MMP2 C-1306T, andMMP9 C-1562T genotyping were
SNPs Associated with Preeclampsia
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performed by PCR-RFLP analysis on a Veriti equipment (Applied Biosystems, CA., USA) fol-
lowed by 3% agarose gel electrophoresis stained with ethidium bromide visualized under UV
light. Table 1 summarizes primers, annealing temperatures, enzymes used, and fragments
obtained. Genotypes for the VNTR of intron 4 of NOS3 were determined by FAM-labeled
PCR, subsequently diluted at a ratio of 1 to 10 with distilled water, added to a mixture contain-
ing formamide (Hi-Di, Applied Biosystems, CA, USA) and standard marker (LIZ 500, Life
Technologies), to a final volume of 10uL. The amplified fragments were denaturated at 95°C
and separated via capillary electrophoresis performed in an automatic DNA Analyzer (ABI
3500 Genetic Analyzer, Applied Biosystems, CA, USA). Automatic sequencing was performed
for validation of PCR-RFLP using random samples including all genotypes in all three genes
using the Big Dye Terminator Cycle Sequencing Ready Reaction Kit v3.1 (Applied Biosystems,
CA, USA) according to the manufacturer's instructions for subsequent electrophoresis in auto-
matic sequencer (ABI 3500 Genetic Analyzer). Sequences obtained were analyzed and com-
pared with public databases (http://www.ncbi.nih.nlm.gov).
Statistical analysis
Clinical and laboratorial data were tabulated in a spreadsheet using Microsoft Excel 2003–2013
(Microsoft, USA) and subsequently exported and analyzed with GraphPad Prism 5.0 software
(GraphPad Software, USA). Genotypic and association studies were performed using R soft-
ware v3.1.2 (The R Foundation for Statistical Computing, USA) with the statistical analysis
packages SNPassoc and epicalc.
Results
A total of 383 pregnant women were enrolled in this study fromMarch 2011 to July 2014.
Forty samples were excluded due to inadequate storage of blood tubes compromising DNA
quality or failure to collect minimum clinical data confirming case or control group allocation.
There was a total of 77 cases of preeclampsia and 266 control pregnant women. Both groups
did not differ significantly in height, pre-gestational weight, body mass index, the percentage of
primigravidas, or of women reporting a smoking habit. Preeclamptic women presented at
Table 1. Sequences of primers, annealing temperatures, and enzymes used in PCR-RFLPs and sizes of the fragments obtained.
SNP Primer sequences Fragment
size (bp)
Annealing
temperature
Restriction
enzyme
Fragments in wild-
type homozygotes
(bp)
Fragments in
polymorphic
homozygotes (bp)
MMP2
T-1306C
F-5´-CTTCCTAGGCTGGTCCTTACTGA-3´ 193 58°C Xsp I 186+7 162+24+7
R-5´-CTGAGACCTGAAGAGCTAAAGAGC-
3´
MMP9
C-1562T
F-5´-GCCTGGCACATAGTAGGCCC-3´ 436 60°C Nla3 381+48+7 246+135+48+7
R-5´-CTTCCTAGCCAGCCGGCATC-3´
NOS3
G894T
F-5´-AAGGCAGGAGACAGTGGATGGA-3´ 248 58°C MboI 248 158+90
R-CCCAGTCAATCCCTTTGGTGCTCA-3´
NOS3
T–786C
F-5´-CACCCAGGCCCACCCCAACT-3´ 394 58°C Msp I 394 352+42
R-5´-GCCGCAGGTCGACAGAGAGACT-3´
NOS3
VNTR
F-5´-CTTACTCTCCACTGCTTTTCAGAG-3´
(Martines et al.)
394–448 58°C NA NA NA
R-5´-CGCAGGTCAGCAGAGAGACTAG-3´
SNP, single nucleotide polymorphism; F, forward; R, reverse; bp, base pairs; VNTR, variable number of tandem repeats, NA, not applicable
doi:10.1371/journal.pone.0136693.t001
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earlier gestational age for delivery, were more likely to undergo cesarean section, and their off-
spring was significantly less mature according to Capurro scores, with significantly lower birth
weight (Table 2).
Tables 3 and 4 present the data on genotypes according to SNPs and to group allocation,
major allele frequencies and Hardy-Weinberg equilibria. We detected a higher frequency of the
presence of SNPs in the NOS3 gene in the group of pregnant women with preeclampsia, but
not in theMMP2 andMMP9 genes. In regard to the VNTR in intron 4 of the eNOS encoding
gene, we noticed a greater diversity of alleles in the control population of pregnant women,
with a more frequent appearance of the rare alleles bearing 4 and 6 repetitions (Table 5). Since
in all polymorphisms the alleles were in Hardy-Weinberg equilibrium, we assumed that our
population had no significant inbreeding or specific migration issues that could affect our esti-
mation of genetic frequencies.
Table 6 shows the results of univariate analysis for risk factors for preeclampsia. The most
significant clinical risk factor was previous preeclampsia, while amongst genetic risk factors,
only SNPs in the NOS3 gene were associated with preeclampsia. Subsequent multivariate anal-
ysis showed that only NOS3 T-786C was associated with preeclampsia independently from age,
height, or weight.
Among preeclamptic women, we also obtained clinical data whether they had to be admit-
ted to receive magnesium sulfate to treat severe preeclampsia, if they developed HELLP syn-
drome, or eclampsia. Patients were then assigned a severity score according to the
Table 2. Clinical characteristics of the study population.
Controls (n = 266) Cases (n = 77) P
Age, y 24,5 (24,8–28,0) 26,4 (25,3–28,0) 0.0547
Pre-gestational weight, kg 64,0 (62,4–65,5) 66,3 (63,0–69,6) 0.2556
Height, m 1,60 (1,60–1,62) 1,61 (1,59–1,62) 0.4529
Body mass index, kg/m2 24,6 (24,1–25,1) 25,3 (24,0–26,6) 0.1613
Gestational age at admission, weeks 38,7 (38,4–39,0) 35,2 (34,4–36,0) <0.0001
Neonate weight, g 3138 (3071–3205) 2304 (2082–2525) <0.0001
Neonate Capurro score, weeks 38,5 (38,2–38,8) 35,3 (34,5–36,1) <0.0001
Smoking (%) 25/258 (9.4) 7/74 (9.1) 0.4924
Primigravida (%) 117/266 (44.4) 38/77 (49.4) 0.1764
Previous preeclampsia (%) 15/265 (5.6) 28/77 (35.6) <0.0001
Type of delivery
Vaginal 157 13
Forceps 11 1 <0.0001
Cesarean section 87 61
doi:10.1371/journal.pone.0136693.t002
Table 3. Major allele frequencies and Hardy-Weinberg tests for the study population.
SNP MAF HWE P
NOS3 G894T 0.861 0.65
NOS3 T-786C 0.907 0.51
MMP2 C-1306T 0.747 0.77
MMP9 C-1562T 0.705 0.60
NOS3 VNTR in intron 4 0.805 0.59
SNP, single nucleotide polymorphism; MAF, major allele frequency; HWE, Hardy-Weinberg equilibrium
doi:10.1371/journal.pone.0136693.t003
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complications reported: baseline score for preeclampsia was zero, adding 1 point if admission
to administer magnesium sulfate was indicated, 10 points if HELLP syndrome was diagnosed,
and 100 points if eclampsia ensued, resulting in a score ranging from 0 to a maximum 111
points. We analyzed whether the NOS3 T-786C polymorphism was associated with more
severe preeclampsia among the cases. Simple severity score analysis showed that wild-type
homozygotes TT for this SNP had a mean score of 1.39, while women with either a CT or CC
genotype had a mean score of 14.15. A score above 10 meant that the latter genotype was possi-
bly associated with at least HELLP syndrome. Complementary chi-square analysis of the sub-
group of preeclamptic women showed that, in a recessive model, NOS3 T-786C was
significantly associated with the occurrence of either HELLP syndrome or eclampsia
(P<0.0001). (Fig 1)
Discussion
In this study, we have explored some clinical and genetic risk factors for preeclampsia in a Bra-
zilian population. We have confirmed that preeclampsia represents a relevant maternal and
neonatal comorbidity, with a lower median gestational age upon admission for delivery in
women diagnosed with preeclampsia, as well as less mature neonates, lower birth weight and
higher percentage of women undergoing cesarean section, which in our hospital is only per-
formed upon medical indication. These results support that this comorbidity precipitates births
more prematurely and leads to the development of complications indicating hospitalization of
the mother before the usual term.
Our analysis showed that the main clinical risk factor for preeclampsia was personal history
of preeclampsia in a previous pregnancy, with an OR of 9.21 (95% confidence interval: 3.22–
Table 4. Genotype frequencies of SNPs for the study population.
Wild-type homozygote Heterozygote Polymorphic homozygote Not determined
NOS3894 genotype GG TG TT ND
Cases 42 (55%) 25 (32%) 10 (13%) 0 (0%)
Controls 149 (56%) 101 (38%) 13 (3%) 3 (1%)
NOS3–786 genotype TT CT CC ND
Cases 36 (47%) 29 (38%) 12 (16%) 0 (0%)
Controls 131 (49%) 118 (44%) 15 (6%) 2 (1%)
MMP2–1306 genotype CC CT TT ND
Cases 53 (69%) 23 (30%) 1 (1%) 0 (0%)
Controls 196 (74%) 61 (23%) 4 (2%) 5 (2%)
MMP 9–1562 genotype CC CT TT ND
Cases 60 (78%) 11 (14%) 1 (1%) 5 (6%)
Controls 217 (82%) 43 (16%) 3 (1%) 3 (1%)
ND, not determined
doi:10.1371/journal.pone.0136693.t004
Table 5. Genotype frequencies of NOS3 VNTR in intron 4 for the study population.
NOS3 VNTR intron 4 genotype 4/4 5/5 4/5 4/6 5/6 ND
Cases 0 (0%) 52 (68%) 17 (22%) 1 (1%) 0 (0%) 7 (9%)
Controls 13 (5%) 148 (56%) 78 (29%) 2 (1%) 4 (2%) 21 (8%)
VNTR, variable number of tandem repetitions; ND, not determined
doi:10.1371/journal.pone.0136693.t005
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28.26), but this obviously only applies to the subset of patients in our study that were not primi-
gravidas. Another limitation of this analysis is that we have excluded other clinical factors that
are known to predispose patients to preeclampsia, such as multiple gestation, chronic hyper-
tension, autoimmune diseases, etc. Age was detected as a risk factor, however minor, with an
OR of only 1.04, possibly due to a bias introduced by enrolling slightly older women in the pre-
eclampsia group, despite not reaching statistical significance.
Among the genetic risk factors, it was found that only the SNPs affecting eNOS were signifi-
cantly associated with preeclampsia. These data agree with those from a recent meta-analysis
reporting on European populations in which this association was found[41]. We did not detect
an association with SNPs in genes encoding MMP-2 and MMP-9. While this confirms previous
observations[30,36,38,42], the change in MMP expression already observed by other studies in
association with these SNPs may still be relevant[29,37]. MMPs may be more important in the
process of invasion of the spiral arteries, which is performed by trophoblasts. Since tropho-
blasts carry fetal DNA, such SNPs may be more important if present in the fetal DNA rather
than in maternal DNA, and new studies should be designed to address this possibility. Even
though no particular genotype for the VNTR in intron 4 was associated with preeclampsia in
our population, we found a great variety of alleles in our population, with the appearance of
the rare allele 6, and a higher frequency of the allele with 4 repetitions amongst controls. It has
Table 6. Odds ratios for risk factors for preeclampsia.
Risk factor Odds ratio 95% CI
Age (years) 1.04 1.01.-1.08
Height (cm) 0.98 0.94–1.02
Weight (kg) 1.00 1.00–1.00
Smoking 0.96 0.33–2.40
Previous preeclampsia 9.21 3.22–28.26
MMP2 C-1306T 0.85 0.09–7.68
MMP9 C-1562T 1.22 0.13–11.91
NOS3 G894T (recessive model, TT vs. GT+GG) 2.87 1.21–6.83
NOS3 T–786C (recessive model, CC vs. TC+TT) 3.06 1.37–6.87
CI, confidence interval; values in bold were statistically significant.
doi:10.1371/journal.pone.0136693.t006
Fig 1. Number of preeclamptic patients according to severity score and genotype distributions for
NOS3 T-786C.
doi:10.1371/journal.pone.0136693.g001
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been recognized that Brazil has a population with wide genetic admixture[43,44] and the pres-
ence of these alleles could be explained by this multiethnic background.
In multivariate analysis, the only SNP that remained statistically significant for the risk of
preeclampsia after correction for age, height and weight, and that was independent from other
polymorphisms, was NOS3 T-786C, with an OR 3.56 (95% CI: 1:23 to 10:31). The failure to
identify the association of the G894T SNP with preeclampsia reported in other studies may
derive from differences in sample size, more mixed genetic background, or different inclusion
criteria. We have chosen to include all preeclamptic patients regardless of severity, while some
studies have used only the most severe spectrum of the disease with blood pressure over 160/
100mmHg. A study in a Brazilian population found an association of G894T with preeclampsia
occurring after 34 weeks of gestation, but haplotype analyses on time of onset and occurrence
of preeclampsia both included the -786C allele[45]. The same group found no association
between individual SNPs in the NOS3 gene with the occurrence of preeclampsia[46], and no
differences in nitrite levels across different NOS3 genotypes in preeclamptic women[47]. These
discrepancies within the same region of Brazil may nonetheless reflect some ethnic differences
between the populations studied and, differently from reported by one of the other studies[47],
we have included patients with HELLP syndrome, and our preeclamptic group did not differ
significantly in BMI from the control population, which may have previously influenced the
power to detect the association between preeclampsia and this SNP. It has been demonstrated
that NOS3 T-786C polymorphism reduces eNOS mRNA expression in the placenta[48]. There-
fore, this SNP may result in enzyme deficiency with reduced bioavailability of NO in the pla-
cental tissue, possibly affecting the placentation, trophoblastic invasion of the spiral arteries,
and causing ischemia by local vasoconstriction. Thus, placental circulation could be primarily
predisposed to an imbalance in favor of a constant reduction of placental blood flow, which
can explain the development of placental insufficiency, an important pathophysiological mech-
anism in the development of preeclampsia. Limitations of this study include not having per-
formed measurement of NO or its metabolites in blood samples to correlate with genotypes
and strengthen this hypothesis.
Our data also agree with NOS3 polymorphism being associated with more severe forms of
preeclampsia[49], and in the present study, this SNP was particularly associated with the most
severe complications (HELLP syndrome and eclampsia). Taken together, our genetic analysis
and previous evidence in the scientific literature support that this SNP may not only be associ-
ated, but actually be implicated[50] in the pathogenesis of preeclampsia. NO deficiency can
also exacerbate platelet activation, which favors the formation of microthrombi, generating
microangiopathic hemolytic anemia and thrombocytopenia, typically found in HELLP syn-
drome. Intravascular hemolysis results in free hemoglobin that readily reacts with available
NO, consuming even more of the already low levels of NO, a vicious circle with decreasing NO
bioavailability. Therefore, the association of the NOS3 polymorphism with preeclampsia and
the occurrence of HELLP and eclampsia indicate an important role of NO in the pathophysiol-
ogy of this disease. Therapeutic strategies that improve NO bioavailability may be useful
approaches to be investigated as novel treatment of severe forms and as preventative measure
of complications of preeclampsia.
In summary, our data support that NOS3 T-786C polymorphism is the most important and
independent genetic factor in this study associated with the occurrence of preeclampsia in a
Brazilian population, and may predispose patients to more severe complications, such as
HELLP syndrome and eclampsia.
SNPs Associated with Preeclampsia
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